Results 281 to 290 of about 419,079 (384)

State‐of‐the‐Art Fabrication of Microneedle Patches: A Mini‐Review on Emerging Techniques

open access: yesMedComm – Biomaterials and Applications, Volume 4, Issue 3, September 2025.
This mini‐review explores state‐of‐the‐art microneedle (MN) fabrication techniques, comparing conventional and emerging methods such as electrospinning and bioprinting. The analysis highlights advancements in precision, scalability, and material compatibility, offering insights into optimizing MN design for transdermal drug delivery, diagnostics, and ...
Syed Waqas Ali Shah   +6 more
wiley   +1 more source

Healthcare personnel on the frontline of immunization: Barriers to vaccination and the path to full coverage. [PDF]

open access: yesHum Vaccin Immunother
Aksu SB   +4 more
europepmc   +1 more source

RNA Modifications in Health and Disease

open access: yesMedComm, Volume 6, Issue 9, September 2025.
Changes in these components profoundly affect the m6A methylation process, leading to a range of physiological and pathological alterations. In recent years, research on the post‐translational modifications of these components has advanced, encompassing ubiquitination, phosphorylation, SUMOylation, O‐GlcNAcylation, and lactylation.
Shiqi Li   +5 more
wiley   +1 more source

High Rate of Seroprotection With Heplisav-B in Patients With Inflammatory Bowel Disease. [PDF]

open access: yesJ Clin Gastroenterol
Hegde Y   +5 more
europepmc   +1 more source

Recent Progress in Gene Delivery Systems Based on Gemini‐Surfactant

open access: yesMedComm – Future Medicine, Volume 4, Issue 3, September 2025.
Gene delivery is a key area in biomedicine, where nucleic acids are delivered into cells to treat diseases by modulating genes. The low micelle concentration, effective nucleic acid complexation, and low immunogenicity make Gemini surfactants promising gene delivery vectors.
Peng Qian   +5 more
wiley   +1 more source

Targeting Immune Checkpoints: Basic Signaling Pathways and Clinical Translation in Cancer Therapeutics

open access: yesMedComm – Oncology, Volume 4, Issue 3, September 2025.
Immune checkpoints in tumor immunotherapy. Ligand binding to the receptor inhibits immune cell function, promotes tumor cell immune escape, and suppresses the immune response. The pathways of action are VISTA‐IGSF11, TIM‐3‐Ceacam1, CD47‐SIRPα, CTLA‐4‐CD80/CD86, PD‐L1‐PD‐1, MHC‐1‐LILRB, and CD24 ‐ Siglec ‐10. There are also other immune checkpoints such
Han Sun   +10 more
wiley   +1 more source

The emerging role of the gut microbiota in vaccination responses. [PDF]

open access: yesGut Microbes
Decker V   +6 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy